soul trial oral semaglutide cardiovascular outcomes trial results Abstract 4351008: Comparing in New Users of Versus Other Noninsulin Glucose-Lowering Therapies Forecasting Trial Milestones: A Predictive

Adverse Reactions Occurring at an Incidence of 5% or More and At Least Twice Placebo Among VYVANSE Treated Patients with BED in Clinical Trials The most common adverse reactions (incidence 5% and at a rate at least twice placebo) reported in adults were dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety

Beyond the finger stick CGM devices go beyond finger sticks to provide glucose monitoring throughout the day

It aids in red blood cell production, helping to deliver oxygen and essential nutrients to hair follicles

doi: 10.1136/BMJ.O158 211 VergerAKasADudouetPGoehringerFSalmon-CeronDGuedjE

Note: Nurx is a structurally different GLP-1 platform from most others in this series